Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06926816 · ClinicalTrials.gov registry record · NA
Universal Genetic Testing for Cancer Risk Reduction
A NA study of Genetic Testing, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 600
- Enrollment target
- 1
- Study location
NCT06926816: Recruiting NA study of Genetic Testing, sponsored by NYU Langone Health.
NCT06926816 is a NA study of Genetic Testing that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 600 participants, roughly in line with the 561-participant average among 7 other Genetic Testing trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06926816, a NA study of Genetic Testing, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to see if offering genetic testing for cancer-related genes is feasible and acceptable for patients presenting for gynecology clinic visits, instead of needing to see specialized providers or needing to meet specific criteria. The primary aim to assess the proportion of patients who undergo genetic testing, and the proportion of patients with pathogenic variants.
Primary Outcome
Outcome measure will be assessed via review of electronic medical record (EMR).
Conditions Studied
Interventions
- GENETIC Natera® Empower™ hereditary cancer panel test
- OTHER Specialist Referral
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-03-04 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT06926816 shows while recruiting
NCT06926816 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 561-participant average among 7 other Genetic Testing trials with a reported enrollment target.
The record links to 1 condition, with Genetic Testing appearing as the primary indexed condition, and to 2 interventions - of which Natera® Empower™ hereditary cancer panel test is the first listed.
NCT06926816 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06926816 about?
NCT06926816 is a clinical study titled "Universal Genetic Testing for Cancer Risk Reduction". The purpose of this research study is to see if offering genetic testing for cancer-related genes is feasible and acceptable for patients presenting for gynecology clinic visits, instead of needing to see specialized providers or needing to meet specific criteria. The primary aim to assess the propo...
What is the current status of trial NCT06926816?
This trial is currently recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2025-03-04. Estimated completion is 2027-12-31.
What conditions does trial NCT06926816 study?
This clinical trial studies the following conditions: Genetic Testing.
What interventions are being tested in trial NCT06926816?
The interventions under investigation include: Natera® Empower™ hereditary cancer panel test (GENETIC), Specialist Referral (OTHER).
Who is sponsoring clinical trial NCT06926816?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06926816 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Testing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Direct vs Indirect Methods for Cascade Screening
RECRUITING · NA
-
Addressing Genomic Disparities in Cancer Survivors
RECRUITING · NA
-
Video Education With Result Dependent dIsclosure
RECRUITING · NA
-
Engaging Adolescents in Decisions About Return of Genomic Research Results
ACTIVE NOT RECRUITING · NA
-
Genetic Testing for All Breast Cancer Patients (GET FACTS)
ACTIVE NOT RECRUITING · NA
-
Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI